GLMD (Galmed Pharmaceuticals) Earnings per share growth rate in current year

Official company branding of galmedpharma.com (GLMD)

The financial stability of Galmed Pharmaceuticals (GLMD) relies on the non-cyclical nature of biotech development, where cash is more critical than GDP. The YoY EPS dynamics on the GURU.Markets chart confirm this, while the 40.00 level captures the current state. The company is actively developing the drug Aramchol; however, geopolitical disruptions and sanctions are significantly hindering global certification and the conduct of international clinical trials.

GLMD (Galmed Pharmaceuticals Ltd) Earnings growth in current year history from 07/04/2022 to 09/10/2026

Analytical breakdowns and data insights for company Galmed Pharmaceuticals Ltd (GLMD)

- share price and consensus valuation forecast:
Basic company analysis:GLMD, Galmed Pharmaceuticals
Manufactured product of Galmed Pharmaceuticals Ltd.

This metric is calculated as the percentage deviation of current earnings per share from the value of the same period last year, measuring the efficiency rates of net income generation. This metric allows for an assessment of the issuer's fundamental stability through the dynamics of profit capitalization. For Galmed Pharmaceuticals (GLMD), during a period of organic asset development and pipeline revision, the current level of EPS YoY change reflects the actual productivity of targeted collaborations.